Topic: Cancer treatment
Associate Professor Holst’s team have been working on a new type of anti-cancer drug that can ‘starve’ prostate cancer cells and stop their growth.
Resistance to endocrine therapies is common, affecting around 40% of people who undergo treatment for breast cancer. Dr Caldon’s team investigated the underlying causes of this resistance.
Professor De Fazio’s team investigated a rare and treatment-resistant subtype of ovarian cancer. Their approach has a better chance of predicting which treatments will work.
This project aims to develop a tailored treatment approach for pancreatic cancer, providing more effective options and boosting the chances of a good outcome.
This project aims to discover how a particular protein called BRD4 leads to the development and growth of tumours in children with TERT-rearranged neuroblastoma.
This project is focused on overcoming the problem of relapse of melanoma in patients being treated by immunotherapy with checkpoint inhibitors.
This project aims to reduce the duration, cost and complications of fungal infections, with a significant reduction in cancer patients suffering.
If successful, this study should significantly improve the patient care of those suffering with advanced liver cancer by making drug treatment more effective.
The aim of this project is to discover which melanoma patients will benefit the most from the use of BET inhibitor drug treatment.
This project aims to find out how certain immune cells could be controlled and how they might be used to predict who will respond to immunotherapy.